Smoking Cessation Author: Kumanan Wilson, MD
Editorial changes - 2009-11-18
Author information and module status
Key Points
Population at Risk
Effectiveness/Harms of Counseling or Intervention on Changing Behavior
Effectiveness/Harms of Behavior Change on Clinical Outcomes
Direct Effectiveness of Intervention/Counseling on Clinical Outcomes
Timeline
Cost-Effectiveness
Patient Education
Referral/Consultation
Guidelines

Tables
References
What's New
Patient Information
Additional Resources
Tools

Quality Measures Quality Measures
Key Points
  • Inquire about the smoking status of all patients and determine their willingness to quit, as smoking cessation is associated with a reduction in all-cause mortality, atherosclerotic disease, obstructive lung disease, and some malignancies.A
  • Encourage smoking cessation strongly in patients with coronary artery disease or obstructive lung disease; patients with established coronary artery disease who quit smoking have a large reduction in risk of death compared to patients who continue.A
  • Provide all smokers with a brief counseling intervention to encourage smoking cessation, but especially focus on persons with children because environmental tobacco smoke increases the development of respiratory disease in children.A
  • Recognize that bupropion, nicotine replacement therapy, varenicline, and behavioral counseling all have been shown to be effective aids in smoking cessation and should be offered to all smokers who are interested in quitting.A
  • Encourage smoking cessation before and during pregnancy because cessation reduces the incidence of both preterm labor and low-birth-weight infants.A
  • Recognize that individuals with established obstructive lung disease who are counseled to quit smoking have a slower deterioration of lung function than patients who continue to smoke.A
  • Focus smoking cessation efforts on individuals with children because environmental tobacco smoke increases the development of respiratory disease in children.B
FAQs
Edward Ellerbeck, MD, MPH, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Kumanan Wilson, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.